Saturday, February 15, 2020

Triphenylphosphonium (TPP)‐Based Antioxidants: A New Perspective on Antioxidant Design

This sentence in the full research is important. 

undergone preliminary clinical trials and has provided promising results in
a variety of disease models, including stroke, autoimmune arthritis

Meaning your doctors and stroke hospitals should IMMEDIATELY be contacting researchers to get  followup human research done with protocols created. If not, then they need to be fired, starting with the board of directors.

 

Triphenylphosphonium (TPP)‐Based Antioxidants: A New Perspective on Antioxidant Design

First published: 05 February 2020


Abstract

Mitochondrial oxidative damage and dysfunction contribute to a wide range of human diseases. Considering the limitation of conventional antioxidants and that mitochondria are the main source of reactive oxygen species (ROS) which induce oxidative damage, mitochondria‐targeted antioxidants which can selectively block mitochondrial oxidative damage and prevent various types of cell death have been widely developed. As a lipophilication, triphenylphosphonium (TPP) has been commonly used in designing mitochondria‐targeted antioxidants. Conjugated with the TPP moiety, antioxidants can achieve more than 1000‐fold higher mitochondrial concentration depending on cell membrane potentials and mitochondrial membrane potentials. Herein we discuss the deficiencies of conventional antioxidants and the advantages of mitochondrial targeting, and review various types of TPP‐based mitochondria‐targeted antioxidants. These provide theoretical and background support for the design of new anti‐oxidant.


No comments:

Post a Comment